Skip to main content
Neural Therapeutics Inc. logo

Neural Therapeutics Inc. — Investor Relations & Filings

Ticker · NURL ISIN · CA64134N2032 LEI · 894500KBZO3KS9715774 CSE Manufacturing
Open in API
Filings indexed 141 across all filing types
Latest filing 2025-07-21 Regulatory Filings
Country CA Canada
Listing CSE NURL

About Neural Therapeutics Inc.

https://neuraltherapeutics.ca/

Neural Therapeutics Inc. is an ethnobotanical drug discovery and development company operating in the pharmaceutical and nutraceutical sectors. It focuses on developing therapeutic drugs for mental illnesses, including those related to substance abuse, and over-the-counter dietary supplements. The company integrates modern scientific research with traditional indigenous knowledge regarding psychoactive plants and whole plant extracts. Initial R&D centers on the San Pedro cactus (Echinopsis pachanoi), which contains mescaline. Neural Therapeutics pursues a dual-path strategy to develop both pharmaceutical and nutraceutical products, aiming for whole plant utilization and zero waste.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the execution of two agreements (a research contract with Peru’s SERFOR and an exclusive German distribution agreement) and discussing strategic partnership details. It does not present financial results (ER), detailed financial statements (10-K/IR), a board or management change (MANG), securities transactions (DIRS, SHA, POS), proxy or AGM materials (PSI, AGM-R), M&A takeover documents (TAR), or any specific report publication. It is a general business update/announcement, which in our taxonomy falls under the fallback category for miscellaneous regulatory filings: RNS.
2025-07-21 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 91% confidence The document is a Venture Issuer Basic Certificate under Canadian NI 52-109 certifying the interim financial report and interim MD&A for the period ended April 30, 2025. This is a regulatory form filing rather than the interim report itself, an earnings release, or any other specific category. It does not contain substantive financial statements or management discussion, but is a compliance certification. Therefore it falls under the general Regulatory Filings category (RNS).
2025-06-27 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 80% confidence The document is a standard NI 52-109 Form 52-109FV2 “Venture Issuer Basic Certificate” signed by the CFO certifying the interim filings (interim financial report and MD&A) for the period ended April 30, 2025. It is not the interim report itself nor an announcement of results, but a regulatory compliance certificate under Canadian securities rules. This does not fit into financial reports (IR), earnings releases (ER), or MD&A (MDA) categories. It is a specific regulatory filing, so it falls into the fallback Regulatory Filings category.
2025-06-27 English
Cover letter.pdf
Management Reports Classification · 91% confidence The document is titled “Interim Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended April 30, 2025.” It is a standalone MD&A prepared under Canadian NI 51-102 covering quarterly results, focusing on management’s analysis of performance, trends, and outlook without full financial statements. This aligns with the definition of a Management Report (Code: MDA).
2025-06-27 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive set of unaudited interim condensed financial statements for Neural Therapeutics Inc. for the three and nine months ended April 30, 2025. It includes the Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Cashflows, Statement of Changes in Shareholders' Deficit, and detailed explanatory notes. This content constitutes a formal interim financial report, not an announcement or a summary, and contains substantive financial data. 9M 2025
2025-06-27 English
News release - English.pdf
M&A Activity Classification · 75% confidence The document is a corporate press release, but it includes the announcement that Neural entered into a Strategic Investment and Option Agreement to acquire up to 100% of CWE. This is an M&A transaction announcement (takeover bid). Therefore, it best fits the M&A Activity category (TAR).
2025-06-06 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.